These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oncolytic viruses in melanoma. Robinson C; Xu MM; Nair SK; Beasley GM; Rhodin KE Front Biosci (Landmark Ed); 2022 Feb; 27(2):63. PubMed ID: 35227006 [TBL] [Abstract][Full Text] [Related]
3. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next? Rothermel LD; Zager JS Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405 [TBL] [Abstract][Full Text] [Related]
5. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Gangi A; Zager JS Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216 [TBL] [Abstract][Full Text] [Related]
6. First Oncolytic Viral Therapy for Melanoma. Poh A Cancer Discov; 2016 Jan; 6(1):6. PubMed ID: 26552414 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. Burke EE; Zager JS Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682 [TBL] [Abstract][Full Text] [Related]
8. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Bommareddy PK; Patel A; Hossain S; Kaufman HL Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837 [TBL] [Abstract][Full Text] [Related]
9. Intralesional treatment of metastatic melanoma: a review of therapeutic options. Weide B; Neri D; Elia G Cancer Immunol Immunother; 2017 May; 66(5):647-656. PubMed ID: 28078357 [TBL] [Abstract][Full Text] [Related]
10. Herpes simplex virus oncolytic vaccine therapy in melanoma. Sivendran S; Pan M; Kaufman HL; Saenger Y Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292 [TBL] [Abstract][Full Text] [Related]
12. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342 [TBL] [Abstract][Full Text] [Related]
13. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555 [TBL] [Abstract][Full Text] [Related]
14. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma. Queen D; Samie FH; Zeitouni NC Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542 [No Abstract] [Full Text] [Related]
15. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503 [TBL] [Abstract][Full Text] [Related]
16. Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model. Liu S; Zhang J; Fang S; Zhang Q; Zhu G; Tian Y; Zhao M; Liu F Exp Eye Res; 2021 Jan; 202():108285. PubMed ID: 33039456 [TBL] [Abstract][Full Text] [Related]
17. Talimogene laherparepvec (Imlygic) for unresectable melanoma. Med Lett Drugs Ther; 2016 Jan; 58(1486):8-9. PubMed ID: 26761342 [No Abstract] [Full Text] [Related]
18. Oncolytic Virotherapy: A Contest between Apples and Oranges. Russell SJ; Peng KW Mol Ther; 2017 May; 25(5):1107-1116. PubMed ID: 28392162 [TBL] [Abstract][Full Text] [Related]
19. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413 [TBL] [Abstract][Full Text] [Related]
20. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]